MSMalcolm A. Smith

Malcolm A. Smith

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Malcolm A. Smith has a total of 95 co-authors. Here are the top co-authors by number of shared publications:

  • Peter J. Houghton

    Nationwide Children's Hospital, Columbus, Ohio

    4 shared publications
  • CP REYNOLDS

    Pediatric Cancer Research Center and Department of Pediatrics, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA

    3 shared publications
  • Christopher L. Morton

    St. Jude Children’s Research Hospital, Memphis, TN

    3 shared publications
  • Min H. Kang

    Texas Tech University Health Sciences Center, Lubbock, Texas

    3 shared publications
  • Richard Simon

    National Cancer Institute Bethesda, Maryland

    3 shared publications
  • Boris Freidlin

    From the National Cancer Institute, Bethesda, and The EMMES Corporation, Potomac, MD; Intergroup Rhabdomyosarcoma Study Committee; Eastern Cooperative Oncology Group; Children's Cancer Study Group; and Pediatric Oncology Group

    2 shared publications

Latest Publications

  • Open Access

    Rethinking the role of synergy calculations in the next century of drug combination discovery

    by Christian T. Meyer, Yunxing Dai, Amy E. Pomeroy, Nathaniel R. Twarog, Andreas Bender, Steven S. Rosenfeld, Emmanuel S. Antonarakis, Jerome T. Mettetal, R. Stephanie Huang, Vito Quaranta, et al.


  • Open Access

    Targeting Pediatric Glioblastomas by Combining OLIG2 Inhibitor CT-179 with Fractionated Radiation in a Panel of Patient-Derived Orthotopic Xenograft Mouse Models

    by Holly Lindsay, Yuchen Du, Lin Qi, Huiyuan Zhang, Sibo Zhao, Frank K. Braun, Mari Kogiso, Clifford Stephan, Gordon Alton, Gregory Stein, et al.

    The poor clinical outcomes of pediatric high-grade glioma (pHGG) highlight the urgent need for new therapies. Oligodendrocyte lineage transcription factor 2 (OLIG2) is a pro-mitotic transcription factor highly expressed in glioma stem cells and may represent a novel therapeutic target. To evaluate the therapeutic efficacy of an OLIG2 inhibitor CT-179 in pHGG, we determined the OLIG2 mRNA expression in 10 patient-derived orthotopic xenograft (PDOX) models. In vitro activities of CT-179 were analyzed in monolayer and neurosphere cells (0–10 µM) with and without radiation (XRT) (0–8 Gy), brain penetration was evaluated in tumor-bearing PDOX mice, and in vivo efficacy was determined at 15–240 mg/kg (oral) alone or combined with XRT (2 Gy/day × 5 days). Changes in animal survival times were analyzed using the Kaplan–Meier method, followed by pair-wise comparisons. Increased OLIG2 mRNA expression was detected in seven out of ten PDOX models. CT-179 inhibited cell viability in a time- and dose-dependent manner in all eight pGBM xenograft tumors (IC50 0.03–10 µM) and was potentiated by XRT (0.03–1 µM). Oral gavage (24 mg/kg) of CT-179 for 5 days led to effective penetration in mouse cerebrum (3232.7 ± 569.2 ng/g), cerebellum (1563.3 ± 269.6 ng/g), brain stem (1685.3 ± 309 ng/g), and PDOX tumors (1814 ± 110.3 ng/g) vs. 361.3 ± 1.5 ng/mL in serum. CT-179 alone was not active at 200 mg/kg in four models, although it was moderately effective at 240 mg/kg in one model. When combined with XRT, a significant extension of animal survival times was observed in two out of four models. Doses needed to eliminate OLIG2 expression in vitro varied from 0.3 to >1 µM in pGBM cells. In summary, our data showed that orally administered CT-179 penetrated the blood–brain barrier (BBB) and exhibited potential for inhibiting pGBM growth when combined with XRT.


  • Evaluation of arsenic trioxide by the pediatric preclinical testing program with a focus on Ewing sarcoma

    by Malcolm A. Smith, Min H. Kang, C. Patrick Reynolds, Raushan T. Kurmasheva, Denise Alexander, Catherine A. Billups, Jeffrey A. Toretsky, Peter J. Houghton

    Arsenic trioxide was tested against the PPTP in vitro panel (1.0 nM to 10 µM) and against the PPTP Ewing sarcoma in vivo panel administered intraperitoneally at a dose of 2.5 mg/kg daily × 5 per week for a planned treatment duration of 3 weeks. Arsenic trioxide showed a median relative IC50 value of 0.9 µM, with Ewing sarcoma cell lines having IC50 values similar to those of the remaining PPTP cell lines. Arsenic trioxide did not induce significant differences in EFS distribution compared to control in any of the Ewing sarcoma xenografts studied, and no objective responses were observed. Pediatr Blood Cancer 2012;59:753–755.


  • Initial testing of the investigational NEDD8‐activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program

    by Malcolm A. Smith, John M. Maris, Richard Gorlick, E. Anders Kolb, Richard Lock, Hernan Carol, Stephen T. Keir, C. Patrick Reynolds, Min H. Kang, Christopher L. Morton, et al.

    Background: MLN4924 is an investigational first‐in‐class small molecule inhibitor of NEDD8‐activating enzyme (NAE). NAE is an essential component of the NEDD8 conjugation pathway, controlling the activity of a subset of ubiquitin‐proteasome system (UPS) E3 ligases, multiprotein complexes that transfer ubiquitin molecules to substrate proteins.Procedures: MLN4924 was tested against the PPTP in vitro panel using 96‐hour exposure time at concentrations ranging from 1.0 nM to 10 µM. It was tested in vivo at a dose of 100 mg/kg [66 mg/kg for the acute lymphoblastic leukemia (ALL) xenografts] administered orally twice daily × 5 days. Treatment duration was 3 weeks.Results: The median relative IC50 for MLN4924 against the PPTP cell lines was 143 nM, (range: 15–678 nM) with that for the Ewing panel being significantly lower (31 nM). MLN4924 induced significant differences in EFS distribution compared to control in 20 of 34 (59%) evaluable solid tumor xenografts. MLN4924 induced intermediate activity (EFS T/C values >2) in 9 of the 33 evaluable xenografts (27%), including 4 of 4 glioblastoma xenografts, 2 of 3 Wilm's tumor xenografts, 2 of 5 rhabdomyosarcoma xenografts, and 1 of 4 neuroblastoma xenografts. For the ALL panel, 5 of 8 evaluable xenografts showed intermediate activity for the EFS T/C measure. MLN4924 did not induce objective responses in the PPTP solid tumor or ALL panels.Conclusions: MLN4924 showed potent activity in vitro and in vivo showed tumor growth inhibitory activity against a subset of the PPTP solid tumor and ALL xenografts. Pediatr Blood Cancer 2012;59:246–253.


  • Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program

    by Malcolm A. Smith, John M. Maris, Richard Lock, E. Anders Kolb, Richard Gorlick, Stephen T. Keir, Hernan Carol, Christopher L. Morton, C. Patrick Reynolds, Min H. Kang, et al.

    Background: PG11047 is a novel conformationally restricted analog of the natural polyamine, spermine that lowers cellular endogenous polyamine levels and competitively inhibits natural polyamine functions leading to cancer cell growth inhibition. The activity of PG11047 was evaluated against the PPTP's in vitro and in vivo panels.Procedures: PG11047 was evaluated against the PPTP in vitro panel using 96 hr exposure at concentrations ranging from 10 nM to 100 µM. It was tested against the PPTP in vivo panels at a dose of 100 mg/kg administered by the intraperitoneal route weekly for 6 weeks.Results: In vitro PG11047 demonstrated a concentration–response pattern consistent with cytostatic activity. The median EC50 for PG11047 was 71 nM. Cell lines of the Ewing sarcoma panel had a lower median EC50 value compared to the remaining cell lines in the panel, while cell lines of the neuroblastoma panel had a higher median EC50 value. In vivo PG11047 induced significant differences in EFS distribution compared to control in 5 of 32 (15.6%) of the evaluable solid tumor xenografts and in 0 of 7 (0%) of the evaluable ALL xenografts. The single case of tumor regression occurred in an ependymoma xenograft.Conclusions: Further pediatric development of PG11047 will require better defining a target population and identifying combinations for which there is a tumor‐selective cytotoxic effect. The regression observed for an ependymoma xenograft and the exquisite sensitivity of some Ewing sarcoma cell lines to the antiproliferative effects of PG11047 provide leads for further preclinical investigations. Pediatr Blood Cancer 2011; 57: 268–274.


  • Update on developmental therapeutics for acute lymphoblastic leukemia

    by Malcolm A. Smith

    This is an exciting time in drug development for acute lymphoblastic leukemia (ALL). A confluence of trends makes it likely that highly effective new agents for ALL will be identified in the coming decade. One contributory factor is the development of more representative preclinical models of ALL for testing and prioritizing novel agents. Another important trend in ALL drug development is the increasing understanding at the molecular level of the genomic changes that occur in B-precursor and T-cell ALL. A final important trend is the increasing availability of new agents against relevant molecular targets. Molecularly targeted agents of interest discussed in this review include novel antibody-based drugs targeted against leukemia surface antigens, proteasome inhibitors, mTOR inhibitors, JAK inhibitors, Aurora A kinase inhibitors, and inhibitors of Bcl-2 family proteins.


  • SK‐NEP‐1 and Rh1 are Ewing family tumor lines

    by Malcolm A. Smith, Christopher L. Morton, Doris Phelps, Kevin Girtman, Geoffrey Neale, Peter J. Houghton

    The utility of preclinical models of childhood cancers is contingent upon reliably classifying them with their corresponding clinical counterparts. Molecular tools such as gene expression profiling allow researchers to confirm the similarity between clinical tumors and preclinical models. We describe the use of gene expression profiling to show that SK‐NEP‐1, a cell line previously thought to represent anaplastic Wilms tumor, is instead related to Ewing sarcoma. RT‐PCR confirmed that SK‐NEP‐1 expresses EWS–FLI1 gene fusion transcripts characteristic of Ewing sarcoma, and DNA sequencing demonstrated the joining of exon 7 of EWS with exon 5 of FLI1 for these transcripts. Rh1, which was previously categorized as an alveolar rhabdomyosarcoma cell line, also has a gene expression profile suggestive of Ewing sarcoma and expresses EWS‐FLI1 fusion transcripts in which exon 7 of EWS is joined with exon 6 of FLI1. These examples illustrate the importance of molecularly characterizing pediatric preclinical models used for testing new agents. Pediatr Blood Cancer 2008;50:703–706.


  • Double trouble: Cancer in twins

    by Malcolm Smith


  • Open Access

    An Overview of Progress in Childhood Cancer Survival

    by Malcolm Smith, Martha L. Hare

    Survival for children with cancer has continued to improve over the past 20 years, with 5-year survival rates now approaching 80% and with an increasing number of children surviving into adulthood. In recognition of the need to address important issues for survivors of childhood cancer, the National Cancer Institute (NCI) has supported the Childhood Cancer Survivor Study (CCSS) since 1993. The CCSS has established a cohort of over 14,000 5-year survivors of childhood cancer initially diagnosed between 1970 and 1986 and has obtained comprehensive summaries of treatment received by these survivors through abstraction of medical records for chemotherapy, radiation therapy, and surgical procedures. Survivors in the CCSS cohort completed a baseline questionnaire and follow up questionnaires to provide information about their current status. The CCSS collected buccal cells for DNA isolation from members of the survivor cohort to allow evaluations of the contribution of genetic factors to long-term sequelae of cancer therapy. The CCSS is now poised to expand its contributions through studies designed to gain greater insight into the biological basis for long-term adverse effects of cancer treatment and is enlarging its efforts to include more recently treated cohorts of patients. The experts present at the work group, Moving the Research Agenda Forward for Children With Cancer, offered several possibilities for utilizing CCSS data in expanding research opportunities concerned with cancer survivorship.